Synlico

Synlico is a private, pre-revenue biotech firm pioneering an AI-driven causal inference platform for drug discovery in the cell and gene therapy space. The company leverages single-cell data and causal modeling to predict how genetic and cellular interventions will behave in a patient's specific microenvironment, aiming to overcome the high failure rates of traditional trial-and-error screening. Led by founder and CEO Dr. Jingwei Lu, a seasoned innovator with extensive experience in T-cell engineering, the team combines deep expertise in computational biology, bioinformatics, and machine learning. Synlico's approach targets a fundamental problem in drug development—the disconnect between designed drug action and actual patient response—positioning it in a competitive but high-potential segment of AI for biotechnology.

An AI-powered computational platform integrating single-cell bioinformatics and causal cell modeling to identify causal links between gene interventions and cell behavior in patient microenvironments for predictive drug discovery.

Synlico operates in the competitive AI drug discovery field, facing off against larger, well-funded public companies (e.g., Recursion, Exscientia) and numerous private startups. Its differentiation is the specific emphasis on causal inference within single-cell biology, a niche but potentially powerful approach if successfully validated.